BFG
VRTX icon

Bleakley Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Bleakley Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.14M Buy
18,400
+1,174
+7% +$520K 0.12% 135
2026
Q1 		$7.69M Buy
17,226
+1,632
+10% +$761K 0.12% 142
2025
Q4 		$7.07M Buy
+15,594
New +$6.72M 0.12% 138
2025
Q3 		– Sell
-13,931
Closed -$6.2M – 614
2025
Q2 		$6.2M Buy
13,931
+2,609
+23% +$1.2M 0.16% 127
2025
Q1 		$5.49M Buy
11,322
+2,847
+34% +$1.33M 0.18% 115
2024
Q4 		$3.41M Buy
8,475
+896
+12% +$415K 0.1% 170
2024
Q3 		$3.52M Sell
7,579
-19,448
-72% -$9.34M 0.11% 163
2024
Q2 		$12.7M Sell
27,027
-850
-3% -$369K 0.37% 52
2024
Q1 		$11.7M Buy
27,877
+5,606
+25% +$2.37M 0.34% 57
2023
Q4 		$9.06M Buy
22,271
+3,819
+21% +$1.41M 0.29% 65
2023
Q3 		$6.42M Buy
18,452
+716
+4% +$250K 0.23% 86
2023
Q2 		$6.24M Buy
17,736
+9,704
+121% +$3.27M 0.19% 96
2023
Q1 		$2.53M Buy
8,032
+513
+7% +$154K 0.08% 206
2022
Q4 		$2.17M Buy
+7,519
New +$2.29M 0.08% 232

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bleakley Financial Group's VRTX Position: Q2 2026 in Review

Bleakley Financial Group increased its Vertex Pharmaceuticals (VRTX) stake by 6.8% in Q2 2026, buying an estimated $520K and bringing the position to 18,400 shares worth $9.14M. The position accounts for 0.12% of the portfolio, ranked #135.

Bleakley Financial Group first reported a position in VRTX in Q4 2022 and has held it in 14 quarters since. The position peaked at $12.7M in Q2 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Bleakley Financial Group held 18,400 shares of Vertex Pharmaceuticals worth $9.14M as of Q2 2026.
  • Bleakley Financial Group bought 1,174 Vertex Pharmaceuticals shares in Q2 2026, an estimated $520K.
  • Vertex Pharmaceuticals made up 0.12% of Bleakley Financial Group's portfolio in Q2 2026, its #135 holding.
  • Bleakley Financial Group first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • Bleakley Financial Group's Vertex Pharmaceuticals position peaked at $12.7M in Q2 2024.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Bleakley Financial Group's 13F filing for Q2 2026, filed 5 Aug 2026.